Literature DB >> 20204276

HLA class I antigen and transporter associated with antigen processing downregulation in metastatic lesions of head and neck squamous cell carcinoma as a marker of poor prognosis.

Nobuyuki Bandoh1, Takeshi Ogino, Akihiro Katayama, Miki Takahara, Akihiro Katada, Tatsuya Hayashi, Yasuaki Harabuchi.   

Abstract

HLA class I antigen processing machinery plays a crucial role in the generation of peptides from endogeneously synthesized proteins and in their presentation to cytotoxic T lymphocytes. The purpose of this study was to analyze the downregulation of HLA class I antigen, transporter associated with antigen processing (TAP) and tapasin in primary and metastatic lesions of head and neck squamous cell carcinoma (HNSCC) and to compare TAP, tapasin and HLA class I antigen downregulation in metastatic lesions with that of primary lesions. We analyzed expression levels of TAP1, TAP2, tapasin and HLA class I antigen in 25 primary and autologous metastatic lesions by staining formalin-fixed, paraffin-embedded tissue sections in the immunoperoxidase reaction. We identified the expression levels of TAP1, TAP2, tapasin and HLA class I antigen were coordinately downregulated in both primary and metastatic lesions and were significantly lower in metastatic lesions than in autologous primary lesions tested. HLA class I antigen downregulation in metastatic lesion was significantly associated with reduced disease-free survival of patients (P<0.05). Multivariate Cox proportional hazards model analysis identified negativity of HLA class I antigen as an independent prognostic marker. HLA class I antigen and TAP are likely to be downregulated in metastatic lesions compared with primary lesions in HNSCC. The higher frequency of HLA class I antigen and TAP down-regulation in metastases play a role in the clinical course of the disease.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20204276     DOI: 10.3892/or_00000717

Source DB:  PubMed          Journal:  Oncol Rep        ISSN: 1021-335X            Impact factor:   3.906


  26 in total

1.  Expression of antigen processing and presenting molecules in brain metastasis of breast cancer.

Authors:  Yan Liu; Yoshihiro Komohara; Natalie Domenick; Masasuke Ohno; Maki Ikeura; Ronald L Hamilton; Craig Horbinski; Xinhui Wang; Soldano Ferrone; Hideho Okada
Journal:  Cancer Immunol Immunother       Date:  2011-11-08       Impact factor: 6.968

2.  The immune microenvironment and expression of PD-L1, PD-1, PRAME and MHC I in salivary duct carcinoma.

Authors:  Bin Xu; Achim A Jungbluth; Denise Frosina; Bayan Alzumaili; Nathaniel Aleynick; Elzbieta Slodkowska; Kevin Higgins; Alan Ho; Luc Morris; Ronald Ghossein; Nora Katabi
Journal:  Histopathology       Date:  2019-10-02       Impact factor: 5.087

3.  TAP1 down-regulation elicits immune escape and poor prognosis in colorectal cancer.

Authors:  Agnes Ling; Anna Löfgren-Burström; Pär Larsson; Xingru Li; Maria L Wikberg; Åke Öberg; Roger Stenling; Sofia Edin; Richard Palmqvist
Journal:  Oncoimmunology       Date:  2017-08-07       Impact factor: 8.110

Review 4.  Checkpoint immunotherapy in head and neck cancers.

Authors:  Paul Zolkind; Ravindra Uppaluri
Journal:  Cancer Metastasis Rev       Date:  2017-09       Impact factor: 9.264

Review 5.  New advances in molecular approaches to head and neck squamous cell carcinoma.

Authors:  Nivedita Sahu; Jennifer Rubin Grandis
Journal:  Anticancer Drugs       Date:  2011-08       Impact factor: 2.248

6.  Identification of an epigenetic profile classifier that is associated with survival in head and neck cancer.

Authors:  Graham M Poage; Rondi A Butler; E Andrés Houseman; Michael D McClean; Heather H Nelson; Brock C Christensen; Carmen J Marsit; Karl T Kelsey
Journal:  Cancer Res       Date:  2012-04-16       Impact factor: 12.701

Review 7.  How patients with an intact immune system develop head and neck cancer.

Authors:  Sarah Greene; Priya Patel; Clint T Allen
Journal:  Oral Oncol       Date:  2019-03-18       Impact factor: 5.337

8.  Multiparametric immune profiling in HPV- oral squamous cell cancer.

Authors:  Zipei Feng; Daniel Bethmann; Matthias Kappler; Carmen Ballesteros-Merino; Alexander Eckert; R Bryan Bell; Allen Cheng; Tuan Bui; Rom Leidner; Walter J Urba; Kent Johnson; Clifford Hoyt; Carlo B Bifulco; Juergen Bukur; Claudia Wickenhauser; Barbara Seliger; Bernard A Fox
Journal:  JCI Insight       Date:  2017-07-20

Review 9.  Immunological and clinical significance of HLA class I antigen processing machinery component defects in malignant cells.

Authors:  Fernando Concha-Benavente; Raghvendra Srivastava; Soldano Ferrone; Robert L Ferris
Journal:  Oral Oncol       Date:  2016-06-02       Impact factor: 5.337

10.  Defective HLA class I antigen processing machinery in cancer.

Authors:  Lei Cai; Theodoros Michelakos; Teppei Yamada; Song Fan; Xinhui Wang; Joseph H Schwab; Cristina R Ferrone; Soldano Ferrone
Journal:  Cancer Immunol Immunother       Date:  2018-02-27       Impact factor: 6.968

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.